1-2 of 2
Michelle Purdom, PhDRN
Close
Sort by
Journal Articles

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

Anthony R. Mato, MDMSCE, Jakub Svoboda, MD, Eline T. Luning Prak, MD,PhD, Stephen J. Schuster, MD, Patricia Tsao, MD PhD, Colleen Dorsey, BSN, RN, Pamela S. Becker, MD, Danielle M. Brander, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Cara M King, MPH, Beth Morrigan, Kaitlin Kennard, RN, BSN, Lindsey E. Roeker, MD, Andrew D. Zelenetz, MD PhD, Michelle Purdom, PhDRN, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Mazyar Shadman, MD MPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 297.
https://doi.org/10.1182/blood-2018-99-117526
Published: 2018
Journal Articles

Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

Anthony R. Mato, MD, Colleen Dorsey, BSN, RN, Elizabeth T Chatburn, BS, Jessica Geoghegan, Stephen J. Schuster, MD, Jakub Svoboda, MD, Pamela S. Becker, MD PhD, Elise A. Chong, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Kaitlin Kennard, RN, BSN, Eline Luning-Prak, MD PhD, Patricia Tsao, MD PhD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Michelle Purdom, PhDRN, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Mazyar Shadman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3010.
https://doi.org/10.1182/blood.V130.Suppl_1.3010.3010
Published: 2017